Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

darexaban glucuronide

 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

AzepinesBenzamidesGlucuronides

Narrower (1)

YM-222714

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
We investigated the effects of ketoconazole on the pharmacokinetics (PK) of the direct clotting factor Xa inhibitor darexaban… Expand
Is this relevant?
2013
2013
Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans
1. The absorption, metabolism and excretion of darexaban (YM150), a novel oral direct factor Xa inhibitor, were investigated… Expand
Is this relevant?
2013
2013
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
AIMS We investigated the effects of rifampicin on the pharmacokinetics (PK) of the direct clotting factor Xa inhibitor darexaban… Expand
Is this relevant?
2013
2013
Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
The oral direct factor Xa inhibitor darexaban administered intraduodenally prevented venous thrombus formation in both rats and… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant…
Here, we investigated the anticoagulant effects of darexaban in mice and human plasma in vitro, effects of darexaban in… Expand
Is this relevant?
2013
2013
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
BACKGROUND Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial… Expand
  • table 1
  • table 2
  • table 2
  • figure 1
  • table 4
Is this relevant?
2013
2013
Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects.
BACKGROUND Darexaban is a potent direct factor Xa (FXa) inhibitor developed for prophylaxis of venous and arterial thromboembolic… Expand
Is this relevant?
2012
2012
Identification of enzymes responsible for the N-oxidation of darexaban glucuronide, the pharmacologically active metabolite of darexaban, and the glucuronidation of darexaban N-oxides in human liver…
Darexaban maleate is a novel oral direct factor Xa inhibitor. Darexaban glucuronide (YM-222714) was the major component in plasma… Expand
Is this relevant?
2012
2012
Darexaban has high sensitivity in the prothrombin time clotting test.
Most synthetic factor Xa (FXa) and thrombin inhibitors examined in pharmacokinetic studies and phase II/III clinical trials have… Expand
  • figure 1
Is this relevant?
2011
2011
Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Darexaban (YM150) is an oral factor Xa inhibitor developed for the prophylaxis of venous and arterial thromboembolic disease… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE